Kinetics and prognostic value of soluble VCAM-1 in ST-segment elevation myocardial infarction patients - Archive ouverte HAL Access content directly
Journal Articles Immunity, Inflammation and Disease Year : 2021

Kinetics and prognostic value of soluble VCAM-1 in ST-segment elevation myocardial infarction patients

(1, 2) , (3) , (3) , (3) , (4, 5) , (1, 6) , (3) , (7, 1) , (6, 7, 1) , (6, 7, 1) , (1, 6) , (1, 6) , (1, 6) , (3) , (3) , (3) , (3) , (3) , (3)
1
2
3
4
5
6
7

Abstract

BACKGROUND: Soluble vascular cell adhesion molecule-1 (sVCAM-1) is a biomarker of endothelial activation and inflammation. There is still controversy as to whether it can predict clinical outcome after ST-elevation myocardial infarction (STEMI). Our aim was to assess the sVCAM-1 kinetics and to evaluate its prognostic predictive value. METHOD: We prospectively enrolled 251 consecutive STEMI patients who underwent coronary revascularization in our university hospital. Blood samples were collected at admission, 4, 24, 48 h and 1 month after admission. sVCAM-1 serum level was assessed using ELISA assay. All patients had cardiac magnetic resonance imaging at 1-month for infarct size (IS) and left ventricular ejection fraction (LVEF) assessment. Clinical outcomes were recorded over 12 months after STEMI. RESULTS: sVCAM-1 levels significantly increased from admission up to 1 month and were significantly correlated with IS, LVEF, and LV end-systolic and diastolic volume. (H48 area under curve (AUC) ≥ H48 median) were associated with an increased risk of adverse clinical events during the 12-month follow-up period with a hazard ratio (HR) = 2.6 (95% confidence interval [CI] of ratio = 1.2-5.6, p = .02). The ability of H48 AUC for sVCAM-1 to discriminate between patients with or without the composite endpoint was evaluated using receiver operating characteristics with an AUC at 0.67 (0.57-0.78, p = .004). This ability was significantly superior to H48 AUC creatine kinase (p = .03). CONCLUSIONS: In STEMI patients, high sVCAM-1 levels are associated with a poor clinical outcome. sVCAM-1 is an early postmyocardial infarction biomarker and might be an interesting target for the development of future therapeutic strategies.
Fichier principal
Vignette du fichier
iid3.409.pdf (1.33 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03344392 , version 1 (15-09-2021)

Identifiers

Cite

A. Hayek, A. Paccalet, L. Mechtouff, C. C. da Silva, F. Ivanes, et al.. Kinetics and prognostic value of soluble VCAM-1 in ST-segment elevation myocardial infarction patients. Immunity, Inflammation and Disease, 2021, 9 (2), pp.493-501. ⟨10.1002/iid3.409⟩. ⟨inserm-03344392⟩
15 View
20 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More